8-K: Inhibikase Therapeutics Announces Phase 2 Trial Results for Risvodetinib in Parkinson's Disease

Inhibikase Therapeutics reports Phase 2 trial results for risvodetinib in Parkinson's disease, meeting its primary safety endpoint but showing mixed efficacy results.

Summary

• Inhibikase Therapeutics announced results from its Phase 2 trial (201 Trial) evaluating risvodetinib for untreated Parkinson's disease.
• The trial involved 126 participants diagnosed with Parkinson's within 14 months, who were administered 50mg, 100mg, 200mg of risvodetinib or a placebo over 12 weeks.
• The primary endpoint of safety and tolerability was met, with 95% of participants completing the trial and adverse events comparable to placebo.
• The trial did not demonstrate improvement in the top hierarchical efficacy measure (MDS-UPDRS Parts 2 and 3) at any dose versus placebo.
• However, risvodetinib showed improvement at 100 mg in Part 2 of the MDS-UPDRS (-1.41 points, p=0.036) and at 50 mg in the Schwab & England Activities of Daily Life Scale (+4%, p=0.0004).
• Skin biopsy analysis suggested a treatment-dependent reduction in neuronal alpha-synuclein deposition across all doses.
• The company will pause further development of risvodetinib and focus on its IkT-001Pro program for pulmonary arterial hypertension (PAH), while considering strategic options for risvodetinib.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the trial met its safety endpoint and showed some positive signals in secondary endpoints, the failure to improve the primary efficacy measure and the decision to pause development of risvodetinib are concerning.

Positives

• The Phase 2 trial met its primary endpoint of safety and tolerability.
• Risvodetinib demonstrated statistically significant improvements in certain secondary endpoints, including Part 2 of the MDS-UPDRS and the Schwab & England Activities of Daily Life Scale.
• Skin biopsy analysis suggests a treatment-dependent reduction in neuronal alpha-synuclein deposition across all doses of risvodetinib.

Negatives

• Risvodetinib did not demonstrate an improvement in the top hierarchical efficacy measure (MDS-UPDRS Parts 2 and 3) at any dose group versus placebo.
• The company is pausing further development of risvodetinib, indicating that the overall results were not compelling enough to continue development at this time.

Risks

• The company's decision to pause development of risvodetinib introduces uncertainty about the future of that program.
• The company's focus on IkT-001Pro for PAH may face challenges in clinical development and regulatory approval.
• Forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially.

Future Outlook

The company will pause further development of risvodetinib and focus its resources on advancing lead program IkT-001Pro in pulmonary arterial hypertension (PAH) and will consider its strategic options for the risvodetinib program.

Management Comments

• The company will pause further development of risvodetinib as it focuses its resources on advancing lead program IkT-001Pro in pulmonary arterial hypertension (PAH) and will consider its strategic options for the risvodetinib program.

Industry Context

The Parkinson's disease treatment landscape is competitive, with numerous companies developing therapies targeting various aspects of the disease. Inhibikase's risvodetinib targets Abelson Tyrosine Kinases, a novel approach. The decision to focus on PAH suggests the company sees a higher potential for success with IkT-001Pro in that indication.

Comparison to Industry Standards

• The MDS-UPDRS is a standard scale used in Parkinson's disease clinical trials to assess motor and non-motor symptoms.
• Improvements in MDS-UPDRS scores are often compared to those seen in trials of other Parkinson's disease therapies, such as levodopa or newer disease-modifying agents.
• Companies like Biogen, Roche, and UCB are also developing therapies for Parkinson's disease, and their clinical trial results set benchmarks for efficacy and safety.

Stakeholder Impact

• Shareholders may react negatively to the news of pausing risvodetinib development.
• Patients with Parkinson's disease may be disappointed by the lack of significant efficacy in the trial.
• Employees may experience uncertainty due to the shift in focus to the PAH program.

Next Steps

• The company will present the data at a future medical meeting.
• The company will focus on advancing its IkT-001Pro program in pulmonary arterial hypertension (PAH).
• The company will consider its strategic options for the risvodetinib program.

Key Dates